Skip to main content
. 2021 Aug 16;12:680177. doi: 10.3389/fpsyt.2021.680177

Figure 3.

Figure 3

Fetal HR and HR variability (mean ± SE) for each exposure group across AM/pre-dose and PM/post-dose fetal assessments for (A) basal fetal HR, (B) short-term variability, and (C) episodes of high fetal HR variability (post hoc test significance levels: *p < 0.05, **p < 0.01, ***p < 0.001).